Kyverna is seeking clearance for a CAR-T therapy to treat an autoimmune disease, which would be a first for this type of treatment. The company has reported positive data from trials of its therapy in various autoimmune conditions, including stiff person syndrome and rheumatoid arthritis. Other pharmaceutical companies, such as UCB, Lilly, Gilead, and Bristol, are also making significant investments in treatments for autoimmune diseases, including bispecifics and cell therapies.